Continuous deep sedation for patients nearing death in the Netherlands: descriptive study by Rietjens, J.A.C. (Judith) et al.
doi:10.1136/bmj.39504.531505.25 
 2008;336;810-813; originally published online 14 Mar 2008; BMJ
  
Buiting, Paul van der Maas and Agnes van der Heide 
Judith Rietjens, Johannes van Delden, Bregje Onwuteaka-Philipsen, Hilde
  
 death in the Netherlands: descriptive study
Continuous deep sedation for patients nearing
 http://bmj.com/cgi/content/full/336/7648/810
Updated information and services can be found at: 
 These include:
 References
 http://bmj.com/cgi/content/full/336/7648/810#otherarticles
2 online articles that cite this article can be accessed at: 
  
 http://bmj.com/cgi/content/full/336/7648/810#BIBL
This article cites 27 articles, 12 of which can be accessed free at: 
Rapid responses
 http://bmj.com/cgi/eletter-submit/336/7648/810
You can respond to this article at: 
  
 http://bmj.com/cgi/content/full/336/7648/810#responses
for free at: 
10 rapid responses have been posted to this article, which you can access
 service
Email alerting
box at the top left of the article 
Receive free email alerts when new articles cite this article - sign up in the
Topic collections
 ( articles) End of life decisions (ethics) 
 ( articles) Assisted dying 
 ( articles) Drugs: musculoskeletal and joint diseases 
 ( articles) Other anaesthesia 
 ( articles) End of life decisions (palliative care) 
 ( articles) End of life decisions (geriatric medicine) 
 ( articles) General practice / family medicine 
  
Articles on similar topics can be found in the following collections 
 Notes   
To order reprints follow the "Request Permissions" link in the navigation box 
 http://resources.bmj.com/bmj/subscribers
 go to: BMJTo subscribe to 
 on 31 October 2008 bmj.comDownloaded from 
RESEARCH
Continuous deep sedation for patients nearing death
in the Netherlands: descriptive study
Judith Rietjens, postdoctoral researcher,1 Johannes van Delden, professor of medical ethics,2
Bregje Onwuteaka-Philipsen, associate professor,3 Hilde Buiting, junior researcher,1 Paul van der Maas,
professor of public health,1 Agnes van der Heide, associate professor1
ABSTRACT
Objectives To study the practice of continuous deep
sedation in 2005 in the Netherlands and compare it with
findings from 2001.
Design Questionnaire study about random samples of
deaths reported to a central death registry in 2005 and
2001.
Setting Nationwide physician study in the Netherlands.
Participants Reporting physicians received a
questionnaire about the medical decisions that preceded
the patient’s death; 78% (n=6860) responded in 2005
and 74% (n=5617) in 2001.
Main outcome measures Characteristics of continuous
deep sedation (attending physician, types of patients,
drugs used, duration, estimated effect on shortening life,
palliative consultation). Requests for euthanasia.
Results The use of continuous deep sedation increased
from 5.6% (95% confidence interval 5.0% to 6.2%) of
deaths in 2001 to 7.1% (6.5% to 7.6%) in 2005, mostly in
patients treated by general practitioners and in thosewith
cancer (in 2005, 47% of sedated patients had cancer v
33% in 2001). In 83% of cases sedation was induced by
benzodiazepines, and in 94% patients were sedated for
periods of less than oneweek until death. Nine per cent of
those who received continuous deep sedation had
previously requested euthanasia but their requests were
not granted.Nineper cent of thephysicians had consulted
a palliative expert.
Conclusions The increased use of continuous deep
sedation forpatientsnearingdeath in theNetherlandsand
the limited use of palliative consultation suggests that
this practice is increasingly considered as part of regular
medical practice.
INTRODUCTION
Patients nearing death often experience distressing
symptoms.1 2 Many patients and physicians are con-
fronted with complex decisions about practices sur-
rounding end of life care that can affect the mode of
dying. As an option of last resort, sedating drugs can be
used. Such drugs induce a state of decreased con-
sciousness and take away the patient’s perception of
symptoms. Sedation can be used intermittently or
continuously until death, and the depth of the sedation
can vary from a lowered state of consciousness to
unconsciousness. All these varieties are covered by the
term palliative sedation, but sedation to unconscious-
ness is also referred to as “terminal sedation.”
Physicians, medical organisations, scientists, ethicists,
legal experts, and politicians are debating its use, with
discussions focusing on the most extreme use of
sedation—that is, continuous deep sedation until
death. An important aspect of the debate concern the
conditions under which this practice is medically
indicated3-8 and the way it is performed.8-11 On the
basis of their expertise and an extensive literature
review, an expert group recently recommended that to
warrant sedation at the end of life, the patient’s
condition should be irreversible and advanced, with
death expected within at most one to two weeks.8
Further recommendations were that benzodiazepines
shouldbe the drugof first choice, that hydration should
beoffered to sedatedpatients onlywhen thebenefitwill
outweigh the harm, and that advice frompalliative care
specialists should be sought before sedation.
Another important aspect of the debate is the
question of when this practice is ethically acceptable.
Is it slow euthanasia or is it a palliative intervention that
should be clearly distinguished from euthanasia?12-16
When the patient’s life expectancy is short when
sedation is started, continuous deep sedation presum-
ably has no or only a limited effect on life shortening
and is generally not considered to be the moral
equivalent of euthanasia. When it is used for patients
with a longer life expectancy with the intention to
hasten the patient’s death at his or her request,
however, this practice should be regarded as the
moral equivalent of euthanasia.
There is a lack of systematic large scale research on
the use of continuous deep sedation because of the
methodological, practical, and ethical difficulties
related to the vulnerability of patients in their last
phase of life. Most studies focus on particular settings
and use different definitions. In 2001, a large scale
study in six European countries showed that contin-
uous deep sedation was used until death in 2.5-8.5% of
all deaths, among patients with cancer and other
diseases, andwasprovided inhospital aswell as outside
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hospital.17 For the Netherlands the estimated propor-
tion was 5.6%.17 Another study with a different design
and a broader definition estimated that deep sedation
until death was used in about 10% of all deaths in the
Netherlands in 2001.18
In 2005, as part of a larger study that evaluated the
Dutch Euthanasia Act, we repeated the large scale
nationwide study in the Netherlands.19 The main
findings of this study were that the enactment of the
Dutch Euthanasia Act was followed by a modest
decrease in the rates of euthanasia (from 2.6% of all
deaths in 2001 to 1.7% of all deaths in 2005) and an
increasedapplicationof continuousdeep sedationuntil
death (from 5.6% in 2001 to 7.1% in 2005). The
increased use of a method that evokes such contro-
versy, and at the same time represents an indispensable
last resort option for unbearably suffering patients,
indicates the need for more detailed insight. We
compared consecutive data from 2005 with those
from 2001 to provide an overview of recent develop-
ments in the use of continuous deep sedation in the
Netherlands. We focused on the characteristics of the
practice of continuous deep sedation until death and
the patients who received such sedation.
METHODS
Study design and data collection
In 2005, we created a stratified sample of death
certificates from the central death registry of Statistics
Netherlands to which all deaths are reported.19 We
assigned all 43 959 deaths that occurred between
August and November 2005 to one of five groups,
according to the circumstances of death. In group 1 the
cause of death precluded any physician assistance in
dying (suchas a car crash resulting in instantdeath), and
wedidnot sendout a questionnaire. Sampling fractions
were larger for the groups in which it was more likely
that a physician had assisted in the death. For all
sampled cases in which we could not exclude the
possibility of physician assistance, we sent the attend-
ing physicians a four page questionnaire. The final
sample containedhalf the cases in group5 (information
on the death certificate made an end of life decision
likely), 25% of the cases in group 4 (deaths from cancer
and deaths that were probably preceded by long term
terminal illness), 12.5% of those in group 3 (non-
sudden death from chronic disease), 8.3% of those in
group 2 (sudden death with pre-existing disease), and
all cases in group 1. The 2001 study was similar.20 The
design of both studies was largely the same, and further
details have been described elsewhere.19 20
Questionnaire
For all sampled cases in which we could not preclude
medical decision making before death, we asked the
attending physician whether death had occurred
suddenly and unexpectedly. If cases were reported as
not sudden, we asked the attending physician to fill in a
four page written questionnaire about the medical
decision making that had preceded death. Of the 6860
questionnaires sent out, 5342 were completed and
returned (78% response). The response percentage in
2001 was 74% (n=5189).
In 2005, the question that pertained to our definition
of continuous deep sedation was: “Was the patient
continuously and deeply sedated or kept in coma until
death?” Follow-up questions were “Which medication
was given for sedation?” (midazolam, other benzodia-
zepine, morphine or a morphine derivative, or other
types of medication) and “How long before the
patient’s death was continuous sedation started?” We
asked these questions for all non-sudden deaths. In
2001, physicians were asked “Did the patient receive
drugs, such as barbiturates or benzodiazepines, to keep
him/her continuously in deep sedation or coma until
death?” In 2001, this was asked only for deaths where
an end of life decision had (potentially) hastened death,
such as intensified alleviation of symptoms with a
potential effect on life shortening or the withholding of
potentially life prolonging treatments.
The 2005 questionnaire contained additional ques-
tions referring to aspects of medical care and treatment
before the patient’s death and the presence of
symptoms, despite possible treatment, during the last
24 hours of life. It also asked whether an expert in
palliative care was consulted during the month before
death. Physicians were asked to estimate the effect on
life shortening, if any, of the decision making before
death. We collected data regarding the patient’s age,
sex, and cause of death from the death certificate.
Analyses
The percentages reported are weighted to adjust for
differences in the sampling fractions and for differences
in response rates in relation to the patient’s sex, age,
marital status, region of residence, and place and cause
of death. After adjustment, we extrapolated the
percentages to cover a 12 month period to reflect the
136 402 deaths in the Netherlands in 2005. Weighting
factors were calculated in three steps. Firstly, we took
the inverse of the percentage of deaths sampled from
each group and multiplied the resulting factor by a
second factor that was calculated by dividing the
sampled number of deaths by the number of deaths for
which we received a questionnaire from the physician
Table 1 | Incidence of continuous deep sedation*. Figures are percentages† of patients
with 95%confidence intervalswhere applicable
Continuous deep sedation 2005 Continuous deep
sedation in
conjunction with
ELD, 2001All patients
Not in conjunction
with ELD
In conjunctionwith
ELD
All physicians 8.2 1.0 7.1 (6.5 to 7.6) 5.6 (5.0 to 6.2)
General practitioners 7.4 0.8 6.6 (5.7 to 7.6) 3.9 (3.3 to 4.7)
Clinical specialists 12 2.0 10.0 (8.7 to 11.5) 8.4 (7.0 to 10)
Nursing home
physicians
6.4 0.5 5.9 (4.8 to 7.3) 7.6 (6.3 to 9.1)
ELD=end of life decision that potentially hastened death (such as withholding and withdrawing potentially life
prolonging treatment).
*Concerns all cases of continuous deep sedation in 2005 (n=521), cases of continuous deep sedation in 2005
not provided in conjunction with end of life decision (n=67), and cases of continuous deep sedation provided in
conjunction with end of life decision (n=454 in 2005; n=336 in 2001).
†Weighted for sampling fractions, non-response, and random sampling deviations.
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for each combination of characteristics of patients. The
weighting factor that resulted from step 1 and 2 was
multiplied by a factor that was calculated in the third
step, by dividing the actual number of cases in the
population of dead people in 2005 for each combina-
tionof characteristics of patients by thenumberof cases
from the first two weighting steps.
We calculated confidence intervals for the main
findings.We compared the prevalence of symptoms in
patients for whom continuous deep sedation had been
started during the last 24 hours of life with the
prevalence of symptoms in all patients in whom
death was not sudden. We excluded missing values
when these comprised less than 5% of all cases.
Statistical analyses were performed with SPSS 11.0
(SPSS, Chicago, IL).
RESULTS
Table 1 shows the incidence of continuous deep
sedation in the Netherlands by specialty of the
physician. As reported previously, 19 of all patients
who died in 2005, 8.2% (95% confidence interval 7.6%
to 8.9%) were continuously and deeply sedated until
death. In 7.1% (6.5% to 7.6%) of deaths, such sedation
was provided in conjunction with decisions that
potentially hastened death (such as decisions to with-
hold potentially life prolonging treatments), which is a
significant increase compared with the 5.6% (5.0% to
6.2%) in 2001. This increase was significant among
general practitioners: 3.9% (3.3% to 4.7%) in 2001 v
6.6% (5.7% to 7.6%) in 2005.Compared with the other
specialties, in 2005 the percentage of continuous deep
sedation was highest (10%, 8.7% to 11.5%) in patients
attended by clinical specialists.
Sixty one per cent of patients who received
continuous deep sedation were aged <80 years, while
51%of all deaths in theNetherlands were in those aged
<80 (table 2). In 2005, 47% (42% to 52%) of patients
who received continuous deep sedation had cancer,
compared with 33% (28% to 38%) in 2001. In general
practice, theproportions of thosewith cancerwere72%
in 2005 and 69% in 2001. Among clinical specialists,
continuous deep sedation was also commonly used for
patients with cardiovascular diseases (19%). Nursing
home physicians used continuous deep sedation for
patients with cardiovascular diseases (24%) and dis-
eases related to the nervous system (12%).
For47%ofall patientswhoreceivedcontinuousdeep
sedation, the sedation was started in the last 24 hours
before death (see table 4). For these patients, 42-55%
were reported as experiencing pain, fatigue, dyspnoea,
and unclear consciousness in the last 24 hours of life
and 23% and 21% had confusion and anxiety (table 3).
Most patients had more than one symptom, and 74%
experienced symptoms that are common indications
for sedation—that is, pain, dyspnoea, confusion, or
anxiety. Sedated patients had more symptoms than
other patientswhodidnot die suddenly andmoreoften
experienced dyspnoea, pain, and anxiety.
Table 4 examines the characteristics of the practice
of continuous deep sedation in 2005. No comparable
data were available from 2001. In 83%, continuous
deep sedationwas inducedwith benzodiazepines often
combined with morphine. Such a combination was
most often used by clinical specialists. Morphine was
used without benzodiazepines in 15%. Nursing home
physicians and general practitioners reported using
benzodiazepines relatively often (89% and 87%,
respectively), whereas clinical specialists were more
likely to administer morphine for sedation (19% of
cases). Palliative consultation in the month before
death was quite rare (9%), and most often sought by
Table 2 | Characteristics of patientswho received continuous deep sedation and of all deaths in the Netherlands*. Figures are percentages† of patients
with 95%confidence intervalswhere applicable
All deaths
Patients attended by
All physiciansGeneral practitioners Clinical specialists
Nursing
home
physicians
2005 2001 2005 2001 2005 2001 2005 2001 2005 2001
Age (years):
0-64 19 20 28 34 32 27 11 7 26 (23 to 30) 23 (19 to 27)
65-79 32 35 37 40 38 52 28 46 35 (31 to 40) 47 (42 to 52)
>80 48 46 35 26 30 21 60 47 39 (34 to 44) 30 (25 to 35)
Sex:
Male 49 49 50 48 57 60 44 35 51 (46 to 56) 50 (45 to 55)
Female 51 51 50 52 43 40 56 65 49 (44 to 54) 50 (45 to 55)
Cause of death‡:
Cancer 29 27 72 69 33 19 34 24 47 (42 to 52) 33 (28 to 38)
Cardiovascular disease 32 25 11 6 19 20 24 8 17 (13 to 22) 13 (9 to 18)
Pulmonary disease 10 10 3 8 8 7 2 15 6 (4 to 10) 10 (7 to 14)
Nervous system disease 3 10 1 3 2 8 12 14 4 (2 to 7) 8 (6 to 12)
Other/unknown 26 27 12 14 38 47 27 39 26 (22 to 31) 36 (31 to 42)
*Cases of continuous deep sedation provided in conjunction with end of life decision (n=454 in 2005, n=336 in 2001).
†Weighted for sampling fractions, non-response, and random sampling deviations.
‡Cerebrovascular disease included in diseases of nervous system in 2001 and in cardiovascular diseases in 2005.
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general practitioners (20% of cases). Palliative con-
sultation was positively related to the use of benzodia-
zepines (whether or not combined with other drugs)
(P<0.01). For almost all of the patients for whom
sedation was used, general practitioners and nursing
home physicians withheld artificial nutrition and
hydration,whereas this was true for 30%of the patients
attended by clinical specialists. In two thirds, physi-
cians estimated that the effect of the decision making
before death on shortening life was 24 hours or less. In
6% of the cases, patients were sedated for more than
oneweek (11% among clinical specialists). In 9% of the
cases, the decision to use continuous deep sedationwas
preceded by an explicit request from the patient to end
hisorher lifebymeansof euthanasiaor assisted suicide,
which was not granted. General practitioners reported
this more often (16%) than clinical specialists (4%) and
nursing home physicians (9%). The most frequently
cited reason why the physician had not granted the
patient’s request was that the time frame to complete
the euthanasia procedure was too short—for example,
because of the obligation to consult another physician
(40%, n=24). Other reasons mentioned were that the
suffering of the patient was not considered to be
unbearable (10%, n=4) and that the patient had
withdrawn the request for euthanasia (9%, n=6).
DISCUSSION
In theNetherlands the increase in the useof continuous
deep sedation for patients nearing death mostly
occurred among general practitioners and clinical
specialists, especially for patients with cancer. Patients
for whom sedation was started in the last 24 hours of
their life more often had dyspnoea, pain, and anxiety
than other patients whose death was not sudden. In
about four out of every five patients sedation was
induced with benzodiazepines. Clinical specialists
weremore likely thangeneralpractitioners andnursing
home physicians to use other drugs, mostly morphine.
Physicians rarely sought palliative consultation,
although this happened more often among general
practitioners. In about one in every 10 patients, the use
of continuous deep sedationwas preceded by a request
for euthanasia or assisted suicide that was not granted.
Strengths and weaknesses of the study
The large random samples of death certificates and
high response rates in both years ensure generalisa-
bility to all deaths in the Netherlands. That the study
design was similar in both years, authoritative medical
bodies endorsed the study, and anonymity of patients
and physicians was guaranteed further strengthen the
validity and reliability of our results. In the 2005
questionnaire, there were small adjustments in the
wording of the key questions regarding the use of
continuous deep sedation. Because we did not change
the key elements of our definition (continuous and
deep sedation or coma until death) we believe this did
not affect our results.
Strengths and weaknesses in relation to other studies
To minimise possible differences in the perception of
sedation across the respondentsweprovided themwith a
descriptive definition of the practice (continuous deep
sedationuntildeath).Mostother studiesuse termssuchas
palliative or terminal sedation, which can have varying
connotations and implications for normal practice.
In 2005 continuous deep sedation until death was
used in 8.2%of all deaths.The proportionof continuous
deep sedation was highest (10%) among patients
attended by clinical specialists compared with the
other specialties. This is in line with a study performed
in six European countries in 2001, where the highest
rates of continuous deep sedation were also found
among patients who died in hospitals compared with
elsewhere (2.9-13.2%), except for Italy, where sedation
rates were higher outside the hospital.17 Furthermore,
our findings show an increase in the use of continuous
deep sedation until death in the studied period,
especially among general practitioners. This agrees
with results of another Dutch longitudinal study.21
While half of the sedated patients in our study had
cancer, continuous deep sedation was also used for
patients with cardiovascular diseases, pulmonary
diseases, and diseases of the nervous system, similar
to the2001European study.17Mostother studies report
the use of continuous deep sedation only for patients
with cancer, probably because they were restricted to
specific settings such as palliative care units.22-25
Furthermore, in the last 24 hours of life, many patients
for whom sedation was started in this period experi-
enced dyspnoea, pain, and fatigue. Anxiety and
confusion were reported for one in five patients.
Symptoms reported by other studies were not
restricted to the last 24 hours and focused on
indications rather than on symptoms. In those studies,
delirium or terminal restlessness, dyspnoea, and pain
Table 3 | Signs or symptoms* in last 24 hours of life for deaths precededby continuous deep
sedation and for all other non-sudden deaths in 2005. Figures are percentages† of patients
with 95%confidence intervals
Continuous deep sedation‡ All non-sudden deaths§
Symptoms:
Fatigue 55 (49 to 61) 48 (46 to 50)
Dyspnoea 48 (42 to 54) 31 (29 to 33)
Unclear consciousness 47 (41 to 53) 40 (38 to 42)
Pain 42 (36 to 48) 19 (18 to 20)
Confusion 23 (18 to 29) 18 (17 to 19)
Anxiety 21 (16 to 27) 9 (8 to 10)
Vomiting 5 (3 to 8) 4 (4 to 5)
Depressive symptoms 3 (1 to 6) 3 (3 to 4)
No of symptoms:
0 7 17
1 22 32
2 27 27
≥3 43 24
*Score 4 or 5 on a scale of 1 (symptom not present) to 5 (symptom strongly present despite treatment).
†Weighted for sampling fractions, non-response, and random sampling deviations
‡In patients in whom sedation was started in 0-24 hours before death (n=238). Symptoms missing for 6-16% of
patients.
§Excludes cases of continuous deep sedation (n=3334). Symptoms were missing for 7-14% of patients.
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are frequent ly ment ioned indicat ions for
sedation,18 22-24 26 27 which seems to agree with our
findings.
We found that 15% of patients were sedated with
morphine as a single therapy. Two other nationwide
Dutch studies conducted in 2001 and 2005 found
somewhat higher levels of use (36%18 and 28%,10
respectively). Similar to our findings, both studies
showed that clinical specialists were more likely than
general practitioners and nursing home physicians to
use morphine for this purpose.10 18Most patients (94%)
were sedated for less than one week, which is also
comparable with results of other studies.22-24 28
Interpretation
There could be several explanations for the increase in
the use of continuous deep sedation until death seen
between 2001 and 2005. Physicians and medical
authorities have paid more attention to continuous
deep sedation and knowledge has increased. From
2002 on, for example, regional cancer centres have
published guidelines to improve its application, and in
2005 (after our data collection) a nationwide guideline
was released in the Netherlands.29 The practice of
continuous deep sedation until death also recently
received a lot of attention in the media. These
developments could have led to an increased interest
in its use among physicians as well as patients and their
relatives.
Continuous deep sedation has possibly increasingly
been used as a relevant alternative to euthanasia. The
use of euthanasia haddecreased from2.6%of all deaths
in 2001 to 1.7%of all deaths in 2005 (a decrease of 1200
cases),19 while continuous deep sedation increased by
1800 cases from 5.6% to 7.1%. This increase took place
mostly in the subgroups in which euthanasia is most
common: patients attended by general practitioners
and those with cancer. In 9% of the patients, the use of
continuous deep sedation was preceded by a request
for euthanasia that was not granted. Although eutha-
nasia and continuous deep sedation generally address
different clinical problems,16 this suggests that sub-
stitutionmight be possible in some situations. This is in
line with the finding that many Dutch physicians have
been found to consider high quality end of life care as
analternative to euthanasia.20Wedonotknowwhether
such substitution is always in accordance with the
patient’s wishes and with legal and professional guide-
lines. As long as the life expectancy of the patient is
short at the time that sedation is started, continuous
deep sedation presumably has no or only a limited
effect on life shortening. In such cases, continuousdeep
sedation might be considered as normal medical
practice, which does not require special judicial super-
vision such as with euthanasia. For patients with a
longer life expectancy, there is a risk that labelling the
decision as continuous deep sedation instead of ending
of life might serve as a way to evade the procedural
Table 4 | Characteristics of continuous deep sedation in 2005*. Figures are percentages† of physicians
General practitioners Clinical specialists Nursing home physicians All physicians
Drugs administered:
Benzodiazepines 42 13 44 30
Benzodiazepines and morphine 44 60 43 51
Benzodiazepines and other
drugs
1 3 2 2
Morphine 11 16 10 13
Morphine and other drugs 2 3 0 2
Other drugs 0 5 0 2
Palliative consultation in last
month before death
20 2 5 9
Artificial nutrition or hydration
withheld during sedation
95 30 98 66
Duration of continuous deep sedation:
0-24 hours 43 50 42 47
1-7 days 52 38 58 47
1-2 weeks 3 7 0 4
>2 weeks 2 4 0 2
Estimated shortening of life‡:
None or <24 hours 57 73 64 65
1-7 days 27 17 18 20
1-4 week 6 3 1 4
>1 month 0 3 4 2
Unknown/missing 9 5 13 9
Preceded by request for
euthanasia, not granted
16 4 9 9
*Concerns all cases of continuous deep sedation (n=521).
†Weighted for sampling fractions, non-response, and random sampling deviations.
‡Refers to all medical decision making about end of life.
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requirements for euthanasia. Our study shows, how-
ever, that the estimated effect on life shortening was, in
most cases, limited. Future studies about medical
practices at the end of life should evaluate this in
more detail.
Around 15% of the physicians used morphine
without a benzodiazepine to attain sedation. Most
guidelines at present recommend the use of benzodia-
zepines for deep sedation, while morphine is usually
rejected as a single therapy to attain sedationbecause of
its unpredictable sedative and side effects. A previous
Dutch study suggested that the choice of drugs for
continuous deep sedation is associated with the use of
guidelines and being a palliative expert or consultation
of a palliative care expert.10 Our study confirmed the
relation between consultation and adequate drug use.
Such consultation, however, occurred in only a small
number of the cases in our study, maybe because most
of the physicians consider the application of contin-
uous deep sedation as normal medical practice that is
part of their own expertise or because they were not
well informed about it or did not have access to
palliative consultation. Increased use of palliative
consultation might improve the clinical performance
of continuous deep sedation.
Unanswered questions and future research
Future research should focuson theunderlying reasons
for the use of continuous deep sedation. The perspec-
tives of physicians as well as the wishes of patients and
relatives should be taken into account. Specific
attention should be directed at the substitution of
euthanasia by continuous deep sedation, especially in
general practice because euthanasia in theNetherlands
usually takes place at home. Research should include a
longitudinal timeframe to investigate how the practice
of continuous deep sedation will further develop. This
should be done nationally and internationally to allow
comparisonsand increaseunderstandingof the reasons
for the use of this practice. Lastly, rendering patients
unconscious until death is a far reaching intervention
that has an important impact on the dying process for
both the patient and the relatives. Whether and how
such sedation contributes to a dignified death deserves
further study.
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